Clearmind Medicine to Unveil New CMND-100 Trial Insights with Yale, Johns Hopkins Researchers
CMND sits 94% above its 52-week low of $2.1 on light trading volume (0.1× avg).
Summary
Clearmind Medicine will host a webinar on June 10th to present new insights from its CMND-100 Phase I/IIa clinical trial for Alcohol Use Disorder. This follows the April 14th announcement that the drug candidate met its primary safety and tolerability endpoint. The involvement of researchers from Yale and Johns Hopkins adds significant credibility to the upcoming data presentation. For this micro-cap biotech, any progress on its lead asset is highly material, especially given its recent history of frequent capital raises. Traders will be watching the June 10th webinar for further details.
At the time of this announcement, CMND was trading at $4.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $2.10 to $524.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.